Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 5/20 | 0.53 |
| ▸ | FNTB | P49356 | 5/20 | 0.53 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9033227 | 1.00 | OPRM1 (0.53) | OPRM1OPRD1OPRK1FNTAFNTB | |
| SCHEMBL9033213 | 1.00 | OPRM1 (0.53) | OPRM1OPRD1OPRK1FNTAFNTB | |
| SCHEMBL9033208 | 1.00 | OPRM1 (0.53) | OPRM1OPRD1OPRK1FNTAFNTB | |
| SCHEMBL6428974 | 0.85 | OPRM1 (0.54) | OPRM1OPRD1OPRK1KMT2AMEN1 | |
| SCHEMBL6431468 | 0.85 | OPRM1 (0.54) | OPRM1OPRD1OPRK1KMT2AMEN1 | |
| SCHEMBL6431423 | 0.85 | OPRM1 (0.54) | OPRM1OPRD1OPRK1KMT2AMEN1 | |
| SCHEMBL6431289 | 0.84 | MEN1 (0.61) | OPRM1OPRD1OPRK1KMT2AMEN1 | |
| SCHEMBL6432366 | 0.83 | OPRM1 (0.57) | OPRM1OPRD1OPRK1KMT2AMEN1 | |
| SCHEMBL31037193 | 0.83 | OPRM1 (0.57) | OPRM1OPRD1OPRK1KMT2AMEN1 | |
| SCHEMBL6368127 | 0.83 | OPRM1 (0.57) | OPRM1OPRD1OPRK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015439-B1 | PRENYL TRANSFERASE INHIBITORS | SOD CONSEILS RECH APPLIC (FR) | 2007-04-11 | — | — | EP | disclosed |
| EP-1676855-A2 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (S.C.R.A.S.) (FR) | 2006-07-05 | — | — | EP | disclosed |
| EP-1001764-A4 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6313109-B2 | ANTIPROLIFERATIVE AGENTS; TREATING TUMORS, RESTENOSIS | SOCIETE DE CONSEILS DE RECHERCHES D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2001-11-06 | — | — | US | disclosed |
| US-20010000344-A1 | Prenyl transferase inhibitors | BIOMEASURE INCORPORATED | 2001-04-19 | — | — | US | disclosed |
| US-6180619-B1 | TREATING TUMORS OR RESTENOSIS | BIOMEASURE, INCORPORATED | 2001-01-30 | — | — | US | disclosed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999064395-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5767274-A | TREATING TUMORS OR RESTENOSIS | BIOMEASURE, INCORPORATED (US) | 1998-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000344-A1 | Prenyl transferase inhibitors | FNTA, FNTB, RCE1 | OPRM1 4479/4885OPRD1 4093/4885OPRK1 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.